{"id":4513,"date":"2026-05-20T16:00:07","date_gmt":"2026-05-20T20:00:07","guid":{"rendered":"https:\/\/www.gensight-biologics.com\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/"},"modified":"2026-10-29T19:54:32","modified_gmt":"2026-10-29T18:54:32","slug":"gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026","status":"publish","type":"post","link":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/","title":{"rendered":"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale du 19 mai 2026"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Paris, France, le 20 mai 2026, 18h00 CET<\/strong> \u2013 GenSight Biologics (Euronext&nbsp;: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce que l\u2019ensemble des 28 r\u00e9solutions soumises au vote de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale Mixte des actionnaires, tenue le 19 mai 2026 et pr\u00e9sid\u00e9e par <strong>Laurence Rodriguez<\/strong>, Directrice G\u00e9n\u00e9rale de la Soci\u00e9t\u00e9, a \u00e9t\u00e9 approuv\u00e9.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Au cours de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale, Laurence Rodriguez a r\u00e9pondu aux questions des actionnaires aux c\u00f4t\u00e9s du <strong>Dr Magali Taiel<\/strong>, Directrice M\u00e9dicale, et de <strong>Jan Eryk Umiastowski<\/strong>, Directeur Financier.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les r\u00e9solutions approuv\u00e9es comprennent notamment des d\u00e9l\u00e9gations financi\u00e8res destin\u00e9es \u00e0 permettre \u00e0 la Soci\u00e9t\u00e9 de poursuivre l\u2019ex\u00e9cution de sa strat\u00e9gie de d\u00e9veloppement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le r\u00e9sultat du scrutin par r\u00e9solution et la retransmission de l\u2019Assembl\u00e9e G\u00e9n\u00e9rale sont disponibles sur le site internet de la Soci\u00e9t\u00e9 dans la rubrique Investisseurs (<a href=\"https:\/\/www.gensight-biologics.com\/fr\/investisseurs\/\">https:\/\/www.gensight-biologics.com\/fr\/investisseurs\/<\/a>).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paris, France, le 20 mai 2026, 18h00 CET \u2013 GenSight Biologics (Euronext&nbsp;: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce que l\u2019ensemble des 28 r\u00e9solutions soumises au vote de [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[54],"tags":[],"featured-area":[190],"news-topic":[],"news-type":[82,76],"post-year":[],"class_list":["post-4513","post","type-post","status-publish","format-standard","hentry","category-communiques-de-presse-financiers","featured-area-homepage-carousel","news-type-general-meeting","news-type-corporate"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale du 19 mai 2026 - GenSight Biologics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale du 19 mai 2026 - GenSight Biologics\" \/>\n<meta property=\"og:description\" content=\"Paris, France, le 20 mai 2026, 18h00 CET \u2013 GenSight Biologics (Euronext&nbsp;: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce que l\u2019ensemble des 28 r\u00e9solutions soumises au vote de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"GenSight Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-20T20:00:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-29T18:54:32+00:00\" \/>\n<meta name=\"author\" content=\"Arthus Moulin-Fournier\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Arthus Moulin-Fournier\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/20\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/20\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\\\/\"},\"author\":{\"name\":\"Arthus Moulin-Fournier\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\"},\"headline\":\"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale du 19 mai 2026\",\"datePublished\":\"2026-05-20T20:00:07+00:00\",\"dateModified\":\"2026-10-29T18:54:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/20\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\\\/\"},\"wordCount\":213,\"articleSection\":[\"Communiqu\u00e9 de presse Financier\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/20\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\\\/\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/20\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\\\/\",\"name\":\"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale du 19 mai 2026 - GenSight Biologics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\"},\"datePublished\":\"2026-05-20T20:00:07+00:00\",\"dateModified\":\"2026-10-29T18:54:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/20\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/20\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/2026\\\/05\\\/20\\\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale du 19 mai 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/\",\"name\":\"GenSight Biologics\",\"description\":\"Restoring vision while advancing gene therapy\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.gensight-biologics.com\\\/fr\\\/#\\\/schema\\\/person\\\/ae14918d0ec7c587d729420ef3ca5c18\",\"name\":\"Arthus Moulin-Fournier\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g\",\"caption\":\"Arthus Moulin-Fournier\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale du 19 mai 2026 - GenSight Biologics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/","og_locale":"fr_FR","og_type":"article","og_title":"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale du 19 mai 2026 - GenSight Biologics","og_description":"Paris, France, le 20 mai 2026, 18h00 CET \u2013 GenSight Biologics (Euronext&nbsp;: SIGHT, ISIN : FR0013183985, \u00e9ligible PEA-PME), soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement et \u00e0 la commercialisation de th\u00e9rapies g\u00e9niques innovantes pour le traitement des maladies neurod\u00e9g\u00e9n\u00e9ratives de la r\u00e9tine et du syst\u00e8me nerveux central, annonce que l\u2019ensemble des 28 r\u00e9solutions soumises au vote de [&hellip;]","og_url":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/","og_site_name":"GenSight Biologics","article_published_time":"2026-05-20T20:00:07+00:00","article_modified_time":"2026-10-29T18:54:32+00:00","author":"Arthus Moulin-Fournier","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Arthus Moulin-Fournier","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/#article","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/"},"author":{"name":"Arthus Moulin-Fournier","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18"},"headline":"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale du 19 mai 2026","datePublished":"2026-05-20T20:00:07+00:00","dateModified":"2026-10-29T18:54:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/"},"wordCount":213,"articleSection":["Communiqu\u00e9 de presse Financier"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/","url":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/","name":"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale du 19 mai 2026 - GenSight Biologics","isPartOf":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#website"},"datePublished":"2026-05-20T20:00:07+00:00","dateModified":"2026-10-29T18:54:32+00:00","author":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18"},"breadcrumb":{"@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.gensight-biologics.com\/fr\/2026\/05\/20\/gensight-biologics-annonce-les-resultats-de-son-assemblee-generale-du-19-mai-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.gensight-biologics.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics annonce les r\u00e9sultats de son Assembl\u00e9e G\u00e9n\u00e9rale du 19 mai 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.gensight-biologics.com\/fr\/#website","url":"https:\/\/www.gensight-biologics.com\/fr\/","name":"GenSight Biologics","description":"Restoring vision while advancing gene therapy","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.gensight-biologics.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.gensight-biologics.com\/fr\/#\/schema\/person\/ae14918d0ec7c587d729420ef3ca5c18","name":"Arthus Moulin-Fournier","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/eace44d269d162de11a066bf28b6d0de50aec912351357046a1db52e59b9cbf9?s=96&d=mm&r=g","caption":"Arthus Moulin-Fournier"}}]}},"_links":{"self":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/comments?post=4513"}],"version-history":[{"count":3,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4513\/revisions"}],"predecessor-version":[{"id":9981,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/posts\/4513\/revisions\/9981"}],"wp:attachment":[{"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/media?parent=4513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/categories?post=4513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/tags?post=4513"},{"taxonomy":"featured-area","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/featured-area?post=4513"},{"taxonomy":"news-topic","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-topic?post=4513"},{"taxonomy":"news-type","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/news-type?post=4513"},{"taxonomy":"post-year","embeddable":true,"href":"https:\/\/www.gensight-biologics.com\/fr\/wp-json\/wp\/v2\/post-year?post=4513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}